EFFECT OF ABNORMAL THYROID-FUNCTION ON THE SEVERITY OF GRAVES OPHTHALMOPATHY

被引:175
作者
PRUMMEL, MF
WIERSINGA, WM
MOURITS, MP
KOORNNEEF, L
BERGHOUT, A
VANDERGAAG, R
机构
[1] UNIV AMSTERDAM,ACAD MED CTR,CTR ORBITAL,1105 AZ AMSTERDAM,NETHERLANDS
[2] NETHERLANDS OPHTHALM RES INST,DEPT OPHTHALMOIMMUNOL,AMSTERDAM,NETHERLANDS
关键词
D O I
10.1001/archinte.150.5.1098
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many clinicians have the impression that treatment of thyroid dysfunction ameliorates ophthalmopathy in Graves' disease. The aim of our study was to relate thyroid function to the severity of Graves' ophthalmopathy. We studied 90 patients with Graves' ophthalmopathy and Graves' hyperthyroidism in whom severity of Graves' ophthalmopathy and thyroid function (regardless of antithyroid treatment) were assessed when referred to our institution. Patients were assigned to four groups (A through D) with increasingly severe Graves' ophthalmopathy using Total Eye Score based on the NOSPECS classification. The percentage of dysthyroid patients in each group was determined: group A had 23% dysthyroid patients (5); group B, 32% (9); group C, 61% (14); and group D, 47% (8). More dysthyroid patients were in the groups with severe Graves' ophthalmopathy. We also compared the severity of Graves' ophthalmopathy between euthyroid (n=54) and dysthyroid (n=36) patients: euthyroid patients had less proptosis (19.9±3.5 vs 20.8±3.4 mm), better visual acuity (0.93±0.17 vs 0.88±0.18), and lower Total Eye Score (8.6±6.6 vs 10.6±6.6). We conclude that dysthyroidism is associated with more severe Graves' ophthalmopathy. Our findings suggest that meticulous control of thyroid function also during antithyroid treatment is important in the management of Graves' ophthalmopathy.
引用
收藏
页码:1098 / 1101
页数:4
相关论文
共 37 条
[1]   STUDIES OF HLA-DR EXPRESSION ON CULTURED HUMAN THYROCYTES - EFFECT OF ANTITHYROID DRUGS AND OTHER AGENTS ON INTERFERON-GAMMA-INDUCED HLA-DR EXPRESSION [J].
AGUAYO, J ;
IITAKA, M ;
ROW, VV ;
VOLPE, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 66 (05) :903-908
[2]  
ARANOW H, 1965, J CLIN ENDOCR METAB, V25, P1
[3]   CHOICE OF THERAPY AND CRITERIA FOR ASSESSING TREATMENT OUTCOME IN THYROID-ASSOCIATED OPHTHALMOPATHY [J].
BAHN, RS ;
GORMAN, CA .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1987, 16 (02) :391-407
[4]   STIMULATING EFFECT OF TRIIODOTHYRONINE ON CELL-MEDIATED-IMMUNITY [J].
BALAZS, C ;
LEOVEY, A ;
SZABO, M ;
BAKO, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 17 (01) :19-23
[5]   ORBITAL COBALT IRRADIATION COMBINED WITH SYSTEMIC CORTICOSTEROIDS FOR GRAVES OPHTHALMOPATHY - COMPARISON WITH SYSTEMIC CORTICOSTEROIDS ALONE [J].
BARTALENA, L ;
MARCOCCI, C ;
CHIOVATO, L ;
LADDAGA, M ;
LEPRI, G ;
ANDREANI, D ;
CAVALLACCI, G ;
BASCHIERI, L ;
PINCHERA, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (06) :1139-1144
[6]  
CALISSENDORFF BM, 1986, ACTA OPHTHALMOL, V64, P698
[7]   ACTIVATED (IA+) LYMPHOCYTES-T AND THEIR SUBSETS IN AUTOIMMUNE THYROID-DISEASES - ANALYSIS BY DUAL LASER FLOW MICROFLUOROCYTOMETRY [J].
CHAN, JYC ;
WALFISH, PG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 62 (02) :403-409
[8]   PREVALENCE OF INCREASED INTRAOCULAR-PRESSURE IN GRAVES-DISEASE - EVIDENCE OF FREQUENT SUBCLINICAL OPHTHALMOPATHY [J].
GAMBLIN, GT ;
HARPER, DG ;
GALENTINE, P ;
BUCK, DR ;
CHERNOW, B ;
EIL, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (08) :420-424
[9]   OPHTHALMOPATHY OF GRAVES-DISEASE [J].
GORMAN, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (08) :453-454
[10]  
GORMAN CA, 1983, MAYO CLIN PROC, V58, P515